Low-dose Interleukin-2 for the Reduction of Vascular Inflammation in Acute Coronary Syndromes
Latest Information Update: 13 Jun 2024
At a glance
- Drugs Aldesleukin (Primary)
- Indications Acute coronary syndromes
- Focus Therapeutic Use
- Acronyms IVORY
Most Recent Events
- 07 Jun 2024 Status changed from active, no longer recruiting to completed.
- 05 Jun 2024 Planned End Date changed from 1 Jan 2024 to 1 Aug 2024.
- 05 Jun 2024 Status changed from recruiting to active, no longer recruiting.